Intellia Therapeutics, Inc. (NASDAQ:NTLA) Receives $54.94 Average Price Target from Analysts

Intellia Therapeutics, Inc. (NASDAQ:NTLA - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the eighteen research firms that are covering the stock, MarketBeat reports. Six analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $54.94.

A number of brokerages have recently issued reports on NTLA. Citigroup lowered their price target on Intellia Therapeutics from $25.00 to $19.00 and set a "neutral" rating on the stock in a report on Friday, October 25th. Wedbush restated a "neutral" rating and set a $14.00 price objective on shares of Intellia Therapeutics in a research report on Monday, November 18th. Canaccord Genuity Group reaffirmed a "buy" rating and issued a $90.00 target price on shares of Intellia Therapeutics in a research report on Tuesday, November 19th. Royal Bank of Canada reiterated an "outperform" rating and set a $54.00 target price on shares of Intellia Therapeutics in a research note on Thursday, September 19th. Finally, The Goldman Sachs Group dropped their price target on Intellia Therapeutics from $31.00 to $20.00 and set a "neutral" rating on the stock in a research note on Friday, October 25th.

Institutional Investors Weigh In On Intellia Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the stock. EverSource Wealth Advisors LLC lifted its stake in Intellia Therapeutics by 763.5% in the second quarter. EverSource Wealth Advisors LLC now owns 1,753 shares of the company's stock worth $39,000 after purchasing an additional 1,550 shares during the last quarter. Eastern Bank purchased a new position in shares of Intellia Therapeutics in the 3rd quarter valued at $41,000. Values First Advisors Inc. purchased a new position in Intellia Therapeutics in the third quarter valued at about $54,000. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Intellia Therapeutics by 27.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,674 shares of the company's stock worth $77,000 after acquiring an additional 794 shares in the last quarter. Finally, KBC Group NV lifted its holdings in shares of Intellia Therapeutics by 37.3% during the 3rd quarter. KBC Group NV now owns 3,753 shares of the company's stock valued at $77,000 after purchasing an additional 1,020 shares during the last quarter. Institutional investors own 88.77% of the company's stock.

Intellia Therapeutics Price Performance

NASDAQ NTLA traded down $0.09 during trading hours on Friday, reaching $12.13. 2,819,440 shares of the company's stock traded hands, compared to its average volume of 2,585,170. The firm has a market cap of $1.24 billion, a PE ratio of -2.23 and a beta of 1.83. Intellia Therapeutics has a 52-week low of $11.34 and a 52-week high of $34.87. The firm has a 50-day simple moving average of $14.08 and a 200 day simple moving average of $19.40.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($1.34) EPS for the quarter, topping analysts' consensus estimates of ($1.37) by $0.03. The company had revenue of $9.10 million during the quarter, compared to the consensus estimate of $8.28 million. During the same period in the prior year, the firm earned ($1.38) earnings per share. The business's revenue for the quarter was down 24.1% compared to the same quarter last year. Sell-side analysts forecast that Intellia Therapeutics will post -5.12 EPS for the current fiscal year.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.